(^40) SUPPLIER NEWS l BIOSPECTRUM | SEPTEMBER 2018 | http://www.biospectrumindia.com
US-based leading molecular
diagnostics company, Cepheid
Inc. (a wholly owned subsidiary
of Danaher) unveiled its
newest configuration in the
GeneXpert family of systems,
the GeneXpert Edge, in India
recently. The company also
announced its ‘Make in India’
initiative by announcing
plans to establish their
manufacturing footprint in
the country for Xpert MTB/
RIF test cartridges which run
on the GeneXpert System.
More than 1,200 Cepheid’s
GeneXpert Systems have been
installed in the last 2 years
at various Revised National
Tuberculosis Control Program
(RNTCP) sites in the country
and more than 2.5 million
cartridges were supplied last
year at various centres of
Central TB Division (CTD). The
GeneXpert Edge is expected to
be available in India later this
year. The GeneXpert Edge is a
portable, easy-to-use system,
developed specifically for near-
patient testing, to help support
a one visit test-and-treat
approach. With almost 17,000
systems in 182 countries,
the GeneXpert System is
the world’s most popular
molecular diagnostics system.
Its modular configuration
makes it the most scalable
platform available, delivering
the ability to process from one
to eighty tests simultaneously
— enabling accurate, fast,
and cost-effective test results
in both lower volume point-
of-care settings and higher
volume reference laboratories.
Cepheid to
establish plant
for Xpert MTB/
RIF tests in India
GE Healthcare launches
trial for PET imaging agent
Agilent Technologies receives
sustainability leadership award
GE Healthcare and Lantheus Holdings, Inc., parent company of
Lantheus Medical Imaging, Inc., have started a second Phase 3 clinical
trial of Flurpiridaz 18F (called the AURORA study), an investigational
agent bein g evaluated for the detection of coronary artery disease
(CAD), the most common form of heart disease. The AURORA study
is an international, multicenter study to evaluate diagnostic efficacy
of Flurpiridaz 18F Injection positron-emission tomography (PET)
myocardial perfusion imaging (MPI) in the detection of CAD. In
this prospective, open-label, study, patients with suspected CAD, for
whom an intracoronary angiography (ICA) has been indicated, will
undergo a single-photon emission computed tomography (SPECT)
MPI and Flurpiridaz 18F Injection PET MPI prior to the performance
of coronary angiography. The primary endpoint is the diagnostic
efficacy (sensitivity and specificity) of Flurpiridaz 18F Injection PET
MPI for the detection of significant CAD.
Agilent Technologies Inc.
recently announced that it has
earned the 2018 Sustainability
Leadership Award
from the Business
Intelligence
Group for its
commitment
to sustainability
through innovative
product design. The
Leadership Award,
judged by a volunteer
panel of leaders and
experts in business,
recognizes an organization
whose actions over the last 12
months prove sustainability
is a core business objective.
According to the Business
Intelligence Group,
the Sustainability
Awards
program was
founded with
the mission of
recognizing true
talent and superior
performance in
the business world,
honoring those who
have made sustainability
an integral part of their
business practice.
singke
(singke)
#1